Business Context and Reporting Period
This Form 8-K Current Report was filed by American Vanguard Corporation on November 23, 2011. The filing addresses a significant regulatory development regarding the company's pentachloronitrobenzene (PCNB) product line.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory event rather than financial performance data.
Material Changes
The primary material change is the approval by the United States Environmental Protection Agency (USEPA) of certain registrations for the company's PCNB product line for all major commercial uses. This approval reverses a previous restriction where PCNB had been unavailable in domestic markets since a Stop Sale, Use or Removal Order was issued by the USEPA in August 2010.
Outlook and Management Commentary
Management announced the USEPA approval via a press release attached as Exhibit 99.1. The restoration of PCNB availability for major commercial uses suggests a potential resumption of sales for this product line in the domestic market, though the filing does not provide specific revenue guidance or detailed management commentary on future financial impact.
Investor Verification Checklist
- Verify the specific scope of the USEPA registrations approved for the PCNB product line.
- Confirm the timeline for the resumption of PCNB sales in domestic markets following the August 2010 Stop Sale Order.
- Review the attached press release (Exhibit 99.1) for details on commercial availability and potential revenue impact.
- Check subsequent filings for updated financial results reflecting the return of PCNB sales.